Serum cystatin C and Chemerin levels in diabetic retinopathy

被引:0
作者
Chen, Xuedong [1 ]
Zhao, Shiyong [2 ]
Yu, Tian [3 ]
Zhang, Liqiong [1 ]
Li, Qingjun [1 ]
Yu, Yongbin [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Heilongjiang, Peoples R China
[3] Univ Aberdeen, Sch Med & Dent, Div Appl Sci, Foresterhill, Aberdeen, MD USA
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2017年 / 10卷 / 07期
关键词
Diabetic retinopathy; Cystatin C; Chemerin; diabetes mellitus; INSULIN-RESISTANCE; METABOLIC SYNDROME; DISEASE; INFLAMMATION; NEPHROPATHY; EXPRESSION; MELLITUS; MARKERS; FUTURE;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: To investigate the levels of serum cystatin C (CysC) and chemokine (Chemerin) in patients with diabetic retinopathy (DR) and their roles in the onset and progression of DR. Methods: A total of 150 diabetic patients were enrolled as subjects and randomly divided into three groups: the proliferative DR (PDR) group (n=50), the non-proliferative DR (NPDR) group (n=50) and the control group (diabetes mellitus (DM) alone, n=50). In addition, 50 healthy adults were selected as normal controls. The four groups of patients were compared in demographic characteristics and biomarkers including gender, age, body mass index (BMI), glycosylated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high sensitive C reactive protein (hsCRP), as well as serum cystatin C and Chemerin levels. Besides, Pearson correlation analysis and Logistics regression analysis were performed. Results: The control group was associated with a significant increase in serum CysC and Chemerin levels as compared with the normal control group; the patients with PDR or NPDR showed significantly higher levels than those with diabetes mellitus (DM) alone; and the ones with PDR had significantly higher levels than those with NPDR. The serum CysC and Chemerin levels were significantly different across groups and increased with the severity of the disease (P<0.05). Pearson correlation analysis showed that the serum CysC levels were positively associated with systolic blood pressure (SBP), HbA1c, HOMA-IR, FPG, TG, TC and LDL-C (P<0.05), and the serum Chemerin levels were positively associated with BMI, HOMA-IR, urinary albumin and hsCRP (P<0.05). What's more, the serum CysC levels were also positively associated with the serum Chemerin levels (P<0.05). Multivariate logistic regression analysis indicated that serums CysC and Chemerin were independent risk factors for DR. Conclusion: Elevated serum CysC and Chemerin levels are risk factors for DR, and they play a role in the pathogenesis of DR. Thus they are likely to become potential markers for assessment of DR.
引用
收藏
页码:10827 / 10833
页数:7
相关论文
共 21 条
  • [1] Chemerin is a novel adipokine associated with obesity and metabolic syndrome
    Bozaoglu, Kiymet
    Bolton, Kristy
    McMillan, Janine
    Zimmet, Paul
    Jowett, Jeremy
    Collier, Greg
    Walder, Ken
    Segal, David
    [J]. ENDOCRINOLOGY, 2007, 148 (10) : 4687 - 4694
  • [2] Increased Serum Chemerin Levels in Diabetic Retinopathy of Type 2 Diabetic Patients
    Du, Junhui
    Li, Rong
    Xu, Lin
    Ma, Ranran
    Liu, Jiali
    Cheng, Jing
    Zhang, Zhong
    Sun, Hongzhi
    [J]. CURRENT EYE RESEARCH, 2016, 41 (01) : 114 - 120
  • [3] Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease
    El-Mesallamy, H. O.
    El-Derany, M. O.
    Hamdy, N. M.
    [J]. DIABETIC MEDICINE, 2011, 28 (10) : 1194 - 1200
  • [4] High cystatin C levels predict severe retinopathy in type 2 diabetes patients
    He, Rui
    Shen, Jing
    Zhao, Jun
    Zeng, Hui
    Li, Lianxi
    Zhao, Jungong
    Liu, Fang
    Jia, Weiping
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2013, 28 (09) : 775 - 778
  • [5] Huang HF, 2015, INT J CLIN EXP PATHO, V8, P11470
  • [6] Serum chemerin and vaspin in non-alcoholic fatty liver disease
    Kukla, Michal
    Zwirska-Korczala, Krystyna
    Hartleb, Marek
    Waluga, Marek
    Chwist, Alina
    Kajor, Maciej
    Ciupinska-Kajor, Monika
    Berdowska, Agnieszka
    Wozniak-Grygiel, Elzbieta
    Buldak, Rafal
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (02) : 235 - 242
  • [7] Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients
    Kwon, Young Eun
    Lee, Mi Jung
    Park, Kyoung Sook
    Han, Seung Hyeok
    Yoo, Tae-Hyun
    Oh, Kook-Hwan
    Lee, Joongyub
    Lee, Kyu Beck
    Chung, Wookyung
    Kim, Yeong-Hoon
    Ahn, Curie
    Choi, Kyu Hun
    [J]. YONSEI MEDICAL JOURNAL, 2017, 58 (02) : 380 - 387
  • [8] Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients
    Lee, Seung-Hwan
    Park, Shin-Ae
    Ko, Seung-Hyun
    Yim, Hyeon-Woo
    Ahn, Yu-Bae
    Yoon, Kun-Ho
    Cha, Bong-Yun
    Son, Ho-Young
    Kwon, Hyuk-Sang
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (02): : 241 - 246
  • [9] Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis
    Lehrke, Michael
    Becker, Alexander
    Greif, Martin
    Stark, Renee
    Laubender, Ruediger P.
    von Ziegler, Franz
    Lebherz, Corinna
    Tittus, Janine
    Reiser, Maximilian
    Becker, Christoph
    Goeke, Burkhard
    Leber, Alexander W.
    Parhofer, Klaus G.
    Broedl, Uli C.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (02) : 339 - 344
  • [10] Diet-induced increases in chemerin are attenuated by exercise and mediate the effect of diet on insulin and HOMA-IR
    Lloyd, Jesse W.
    Zerfass, Kristy M.
    Heckstall, Ebony M.
    Evans, Kristin A.
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (05) : 189 - 198